Inputs

As governments and corporates prioritize domestic supply security ahead of lucrative exports, investors are turning to projects that shorten and diversify supply chains.

Cory Steffek says Sedron’s fertilizer and wastewater infrastructure businesses could attract different groups of buyers, with an IPO among the potential exit routes.

DCVC Bio partner Justin Kern says the firm’s ag investments focus on the 'shape' of agtech exits that has emerged and the presence of an obvious acquirer.

Investors who have reduced their reliance on the farm inputs most sensitive to geopolitical clashes – or stockpiled these assets early – can navigate an easier way through the storm.

HGS chief executive Mike Steffeck says microbials are the ‘newest but the least understood’ area of biological inputs and are in high demand from retailers and farmers.

Chief investment officer Angelos Dassios says the buyout makes HGS BioScience one of the most complete biostimulant and bionutritional platforms in North America.

The Australian Sustainable Finance Institute has launched a taxonomy to clarify what investment activities qualify for ‘green’ or ‘transition’ labels, but investors will still need to assess the true climate impact of their portfolios.

Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.

Chief executive Mike Steffeck says this first acquisition since Paine Schwartz’s 2022 investment positions the Jacksonville company for growth into other biostimulant markets.

Pricing pressures and elevated costs have contributed to a sharp decline in returns among permanent cropping assets.